- Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Esperion Reports First Quarter 2024 Financial Results
- Esperion to Participate in Upcoming May Investor Conferences
- Esperion to Report First Quarter 2024 Financial Results on May 7
- Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
- Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024
- Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference
- Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24
- U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
- CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events
More ▼
Key statistics
On Friday, Esperion Therapeutics Inc (ESPR:NMQ) closed at 2.19, -35.59% below its 52-week high of 3.40, set on Apr 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.13 |
---|---|
High | 2.22 |
Low | 2.07 |
Bid | 2.18 |
Offer | 2.20 |
Previous close | 2.09 |
Average volume | 10.14m |
---|---|
Shares outstanding | 189.46m |
Free float | 188.61m |
P/E (TTM) | -- |
Market cap | 414.92m USD |
EPS (TTM) | -1.00 USD |
Data delayed at least 15 minutes, as of May 10 2024 21:00 BST.
More ▼